Navigation Links
Ruboxistaurin (RBX) may prevent vision loss in diabetic patients

Phase III clinical trial of Ruboxistaurin (RBX) at a concentration of 32 milligrams/day// was found to inhibit Protein kinase C (PKC) – beta inhibitor, which was found to cause vision loss in patients with diabetes.

The study was conducted in 252 patients with type 1 or type 2 diabetes by the Research team of Joslin Diabetes Centre across United States, Canada, Denmark, Netherlands and United Kingdom. The study was named as PKS-DRS, (Protein Kinase C – Diabetic Retinopathy Study), was done to evaluate the oral administration of RBX and placebo over a period of 3-4 years at a concentration of 8, 16 or 32 mg/day.

Incidence of eye complications is high in Diabetic patients, with common complications of diabetes causing diabetic retinopathy and diabetic macular edema. Diabetic retinopathy is characterised by damage to small blood vessels in the retina and causes severe vision loss. Diabetic macular edema is characterised by leaky blood vessels with swelling in the retina.

Protein kinase C is required for the normal production of energy in the body, but a-form of PKC has found to cause diabetic complications of the eye. a- PKC is the major signaling pathway which is stimulated by high blood glucose levels. In animal studies it was found that the abnormal activation of a-PKC decreases the blood flow to the retina.

The research team has found oral administration of 32 milligrams/day of Ruboxistaurin, blocks the activity of a-Protein kinase C. Moreover, RBX was found to be specific in binding only to the a-form of PKC. Though, RBX does not prevent the progression of diabetic retinopathy, it reduces the vision loss which is caused by macular edema. RBX in the study group did not produce any side-effects.
'"/>




Page: 1

Related medicine news :

1. Ruboxistaurin As A Novel Treatment For Diabetic Nephropathy
2. Asthma may actually be prevented by Dust and Dirt
3. Nearly all asthma deaths preventable
4. Breast Feeding prevents obesity later on in life
5. Regular exercise prevents hip fractures
6. Gel prevents pregnancy
7. Arterial stiffness prevented by light drinking
8. How to prevent wrinkles?
9. Re-blockage of heart arteries prevented by vitamins
10. Early delivery can prevent cancer
11. Hobbies prevent dementia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ... , ... 21 Middle East and South Asia Leaders Selected as Eisenhower Fellows ... and civil society in 11 countries across the Middle East and South Asia to ... exchange of knowledge and ideas with the leading minds in their fields. , ...
(Date:6/23/2017)... ... 23, 2017 , ... PureLife Dental is pleased to announce that California Dental ... As part of the amalgam separator endorsement, all CDA members may purchase an ECO ... the retail value. This partnership between PureLife and CDA is especially timely as it ...
(Date:6/23/2017)... ... June 23, 2017 , ... American Farmer, will feature Chr. ... is slated to air fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET on ... Danish pharmacist, founded Chr. Hansen in Denmark in 1874 after a groundbreaking discovery of ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... management, financial planning, and related services to families and business owners in and ... charity drive to benefit senior citizens in the area. , Meals on Wheels ...
(Date:6/23/2017)... ... , ... All-Star Insurance, a family managed agency that offers insurance management assistance ... the launch of a new charity drive to benefit women in the area diagnosed ... that an estimated 252, 710 new cases of invasive or high risk breast cancer ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... LAWRENCE, Mass. , June 2, 2017  NxStage ... advancing renal care, today announced new findings demonstrating positive ... NxStage ® System One™. The data will be ... 2017, in Madrid, Spain . ... Knowledge to Improve Home Dialysis Network in ...
(Date:5/29/2017)... TEL AVIV, Israel, May 29, 2017  Cellect Biotechnology ... of innovative technology which enables the functional selection of ... financial results for the first quarter ended March 31 ... pleased with our accomplishments in the first quarter of ... the first quarter, we announced the treatment of the ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
Breaking Medicine Technology: